Back to top
more

Emergent Biosolutions (EBS)

(Real Time Quote from BATS)

$14.30 USD

14.30
1,059,347

+0.49 (3.55%)

Updated Jul 25, 2024 10:44 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Emergent (EBS) Issues Plan to Resume Bayview Facility Operation

by Zacks Equity Research

Emergent (EBS) starts to make improvements at its Baview facility in order to meet FDA's standard and resume production of J&J's COVID-19 vaccine.

Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?

by Zacks Equity Research

Sector ETF report for SBIO

Emergent (EBS) Beats on Q1 Earnings, Cuts Contract Revenue View

by Zacks Equity Research

Emergent's (EBS) earnings in the first quarter of 2021 beat estimates while revenues miss the same. It lowers guidance for revenues from CDMO services. Stock down.

New Strong Sell Stocks for April 30th

by Zacks Equity Research

ARAY, EBS, FARM, SHLX, and TPB have been added to the Zacks Rank #5 (Strong Sell) List on April 30, 2021

Emergent Biosolutions (EBS) Q1 Earnings Top Estimates

by Zacks Equity Research

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 57.73% and -6.95%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Emergent (EBS) This Earnings Season?

by Zacks Equity Research

On Emergent's (EBS) upcoming first-quarter earnings call, investors are likely to focus on the company's update related to re-start of production at its Bayview facility.

Moving Average Crossover Alert: Emergent BioSolutions (EBS)

by Zacks Equity Research

Emergent BioSolutions (EBS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Centene (CNC) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Centene's (CNC) first-quarter results are likely to reflect improving premiums and rise in membership, partly offset by escalating costs.

    Emergent Biosolutions (EBS) Earnings Expected to Grow: Should You Buy?

    by Zacks Equity Research

    Emergent Biosolutions (EBS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Why Emergent Biosolutions (EBS) is Poised to Beat Earnings Estimates Again

    by Zacks Equity Research

    Emergent Biosolutions (EBS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

    J&J (JNJ) Gets Usage Guidance for COVID-19 Vaccine in Europe

    by Zacks Equity Research

    J&J (JNJ) is set to resume shipments of its COVID-19 vaccine to European countries, following positive recommendation from EMA's Pharmacovigilance Risk Assessment Committee (PRAC).

    Emergent (EBS) Bayview Unit Operation on Hold for FDA Probe

    by Zacks Equity Research

    Emergent (EBS) halts manufacturing at Bayview facility as the FDA initiates investigation of the error that led to manufacturing of faulty doses of J&J's COVID-19 vaccine.

    Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates

    by Zacks Equity Research

    The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.

    Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates

    by Zacks Equity Research

    The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.

    Emergent (EBS) Gets Extra $23M for COVID-19 Vaccine Production

    by Zacks Equity Research

    Emergent (EBS) receives additional $23 million from BARDA to support further expansion of manufacturing capacity for Johnson & Johnson's COVID-19 vaccine.

    J&J (JNJ) Gets Full Charge of Emergent COVID-19 Vaccine Plant

    by Zacks Equity Research

    The U.S. government places J&J (JNJ) in charge of Emergent's Baltimore factory. The facility will cease production of AstraZeneca shots.

    Why Is Emergent Biosolutions (EBS) Down 22.3% Since Last Earnings Report?

    by Zacks Equity Research

    Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Emergent (EBS) Beats on Q4 Earnings, Misses on Revenues

    by Zacks Equity Research

    Emergent's (EBS) earnings in the fourth quarter of 2020 beat estimates while revenues miss the same. Sales of contract development and manufacturing services rise.

    Vaxart (VXRT) to Report Q4 Earnings: What's in the Cards?

    by Zacks Equity Research

    On Vaxart's (VXRT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its oral COVID-19 vaccine candidate, VXA-CoV2-1.

    Emergent (EBS) Posts Preliminary '20 Results, Gives 2021 View

    by Zacks Equity Research

    Emergent (EBS) tightens revenue view for 2020 and expects a consistent rise in sales of contract development and manufacturing services provided to other companies.

    3 Reasons Why Growth Investors Shouldn't Overlook Emergent Biosolutions (EBS)

    by Zacks Equity Research

    Emergent Biosolutions (EBS) is well positioned to outperform the market, as it exhibits above-average growth in financials.

    Emergent Biosolutions (EBS) Outpaces Stock Market Gains: What You Should Know

    by Zacks Equity Research

    Emergent Biosolutions (EBS) closed the most recent trading day at $97.97, moving +1.01% from the previous trading session.

    Is Emergent Biosolutions (EBS) Outperforming Other Medical Stocks This Year?

    by Zacks Equity Research

    Is (EBS) Outperforming Other Medical Stocks This Year?

    Company News for Dec 31, 2020

    by Zacks Equity Research

    Companies In The News Are: MKC, EBS, FOXA, AAPL

    Emergent Biosolutions (EBS) Down 14.7% Since Last Earnings Report: Can It Rebound?

    by Zacks Equity Research

    Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.